SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

The alliance expands upon existing collaborations between MD Anderson researchers and Myriad, including ongoing studies in breast cancer and renal cell carcinoma. Myriad Genetics is a leading ...

Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...

Typically, prenatal cell-free DNA (pcfDNA ... Chief Scientific Officer at Myriad Genetics. “We are improving the timeline for patients to understand their risk assessment of chromosomal ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics ... s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation ...